OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Transforming CLL management with immunotherapy: Investigating the potential of CAR T-cells and bispecific antibodies
Azra Borogovac, Tanya Siddiqi
Seminars in Hematology (2024) Vol. 61, Iss. 2, pp. 119-130
Closed Access | Times Cited: 9
Azra Borogovac, Tanya Siddiqi
Seminars in Hematology (2024) Vol. 61, Iss. 2, pp. 119-130
Closed Access | Times Cited: 9
Showing 9 citing articles:
Chronic lymphocytic leukemia: what clinical progress have we seen in the last five years?
Elżbieta Iskierka‐Jażdżewska, Bartosz Puła, Krzysztof Jamroziak, et al.
Expert Opinion on Investigational Drugs (2025)
Closed Access
Elżbieta Iskierka‐Jażdżewska, Bartosz Puła, Krzysztof Jamroziak, et al.
Expert Opinion on Investigational Drugs (2025)
Closed Access
IGLV3-21-R110-directed bispecific antibodies activate T cells and promote killing in a high-risk subset of chronic lymphocytic leukemia
Claudia Fischer, Simon Stücheli, Shih‐Shih Chen, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
Claudia Fischer, Simon Stücheli, Shih‐Shih Chen, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
Leveraging the Immunomodulatory Potential of Ibrutinib for Improved Outcomes of T Cell-Mediated Therapies of B Cell Malignancies: A Narrative Review
David B. Miklos, Peter A. Riedell, Alex Bokun, et al.
Targeted Oncology (2025)
Open Access
David B. Miklos, Peter A. Riedell, Alex Bokun, et al.
Targeted Oncology (2025)
Open Access
The complexities of T-cell dysfunction in chronic lymphocytic leukemia
Elena Camerini, Derk Amsen, Arnon P. Kater, et al.
Seminars in Hematology (2024) Vol. 61, Iss. 3, pp. 163-171
Open Access | Times Cited: 2
Elena Camerini, Derk Amsen, Arnon P. Kater, et al.
Seminars in Hematology (2024) Vol. 61, Iss. 3, pp. 163-171
Open Access | Times Cited: 2
Advancing CAR T-cell therapy for chronic lymphocytic leukemia: exploring resistance mechanisms and the innovative strategies to overcome them
Azra Borogovac, Tanya Siddiqi
Cancer Drug Resistance (2024)
Open Access | Times Cited: 1
Azra Borogovac, Tanya Siddiqi
Cancer Drug Resistance (2024)
Open Access | Times Cited: 1
BCL-2 and BTK inhibitors for chronic lymphocytic leukemia: current treatments and overcoming resistance
Tadeusz Robak, Magdalena Witkowska, Anna Wolska, et al.
Expert Review of Hematology (2024)
Closed Access | Times Cited: 1
Tadeusz Robak, Magdalena Witkowska, Anna Wolska, et al.
Expert Review of Hematology (2024)
Closed Access | Times Cited: 1
Relapsed/refractory CLL: the role of allo-SCT, CAR-T, and T-cell engagers
Arnon P. Kater, Tanya Siddiqi
Hematology (2024) Vol. 2024, Iss. 1, pp. 474-481
Closed Access | Times Cited: 1
Arnon P. Kater, Tanya Siddiqi
Hematology (2024) Vol. 2024, Iss. 1, pp. 474-481
Closed Access | Times Cited: 1
Special issue on chronic lymphocytic leukemia: Prognostication and therapeutic options introductory editorial
Barbara Eichhorst, Elisa ten Hacken
Seminars in Hematology (2024) Vol. 61, Iss. 2, pp. 69-72
Closed Access
Barbara Eichhorst, Elisa ten Hacken
Seminars in Hematology (2024) Vol. 61, Iss. 2, pp. 69-72
Closed Access
Recent Advances and Challenges in Cancer Treatment with Car T Cell Therapy: A Novel Anti-cancer Strategy
Hassan Mellatyar, Sina Sattari, Amir Nezami Asl, et al.
BioNanoScience (2024) Vol. 14, Iss. 4, pp. 4250-4262
Closed Access
Hassan Mellatyar, Sina Sattari, Amir Nezami Asl, et al.
BioNanoScience (2024) Vol. 14, Iss. 4, pp. 4250-4262
Closed Access
Synthesis and Biochemical Evaluation of Ethanoanthracenes and Related Compounds: Antiproliferative and Pro-Apoptotic Effects in Chronic Lymphocytic Leukemia (CLL)
James P. McKeown, Andrew J. Byrne, Sandra A. Bright, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 8, pp. 1034-1034
Open Access
James P. McKeown, Andrew J. Byrne, Sandra A. Bright, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 8, pp. 1034-1034
Open Access
